Everolimus CAS NO.: 159351-69-6 for API By Shenzhen Enzyme Biopharm Co., Ltd,
Pas encore membre de TradeKey.com? Inscrivez-vous pour vous connecter avec 9 millions d'importateurs et exportateurs.
Rejoignez-le maintenant c'est gratuit |
BOOK A CALL
Book Call On Your Favorite Time

By Signing Up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services

Contact Us
product
Prev
Everolimus CAS NO.: 159351-69-6 for API
Next

Everolimus CAS NO.: 159351-69-6 for API

|

1 Gram Minimum Order

Pays:

China

N ° de modèle:

-

Prix FOB:

Localité:

China

Prix de commande minimale:

-

Commande minimale:

1 Gram

Packaging Detail:

bag or drum or carton

Heure de livraison:

15-30 days

Capacité de Fournir:

1000 Ton per Year

Payment Type:

T/T, L/C, D/P

Groupe de produits :

-

Contacter maintenant
Membre gratuit

Personne à contacter Zhang

Guangzhou, Guangdong

Contacter maintenant

Spécification du produit

  • MF: C53H83NO14
  • Type : Immune Function Agents
  • Grade Standard: Medicine Grade
  • Purity (%): 99% or more

La description

everolimus is a derivative of sirolimus, also known as **-o-(*-hydroxyethyl)-rapamycin, or **-o-(*-hydroxyethyl)-sirolimus, which is an oral mammalian rapamycin (mTOR) inhibitor, In the past, it is mainly used to prevent the rejection after kidney transplantation and heart transplantation. The present invention can also be used for the treatment of patients with advanced renal cancer which have been used for the inhibition of vascular endothelial growth factor receptor kinase inhibitors: sunitinib and sorafenib (Nexavar, Bayer), and have less toxic and side effects.  

Pays: China
N ° de modèle: -
Prix FOB: Obtenir le dernier prix
Localité: China
Prix de commande minimale: -
Commande minimale: 1 Gram
Packaging Detail: bag or drum or carton
Heure de livraison: 15-30 days
Capacité de Fournir: 1000 Ton per Year
Payment Type: T/T, L/C, D/P
Groupe de produits : -

Send a direct inquiry to this supplier

To:

Zhang < Shenzhen Enzyme Biopharm Co., Ltd >

Je veux savoir: